✦ LIBER ✦

Prospective randomized study of once-daily versus thrice-daily netilmicin regimens in patients with intraabdominal infections

✍ Scribed by P. J. de Vries; R. P. Verkooyen; P. Leguit; H. A. Verbrugh

Publisher: Springer
Year: 1990
Tongue: English
Weight: 945 KB
Volume: 9
Category: Article
ISSN: 0934-9723
DOI: 10.1007/bf01963832

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A dose-finding study of once-daily oral

A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection

✍ Ching-Lung Lai; Seng Gee Lim; Nathaniel A. Brown; Xiao-Jian Zhou; Deborah M. Llo 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 305 KB 👁 1 views

Current therapy for chronic hepatitis B is suboptimal as a result of limited durable response rates, cumulative viral resistance, and/or poor tolerability. Telbivudine has potent antiviral activity against hepatitis B virus (HBV) in vitro and in the woodchuck model and has a promising preclinical sa

The effect of latanoprost 0.005% once da

The effect of latanoprost 0.005% once daily versus 0.0015% twice daily on intraocular pressure and aqueous humour protein concentration in glaucoma patients. A randomized, double-masked comparison with timolol 0.5%

✍ Michael Diestelhorst; Sigrid Roters; Günter K. Krieglstein 📂 Article 📅 1997 🏛 Springer-Verlag 🌐 English ⚖ 644 KB

Prospective randomized comparison of mor

Prospective randomized comparison of morning versus night daily single subcutaneous administration of granulocyte-macrophage–colony stimulating factor in patients with soft tissue or bone sarcoma

✍ Dilek Dinçol; Mustafa Samur; Ali Pamir; Orhan Şencan; Hakan Akbulut; Bülent Yalç 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB 👁 1 views

## BACKGROUND. Hematopoietic growth factors (HGFs) have been used to reduce the neutropenic complications of cytotoxic chemotherapy so that higher doses may be given. The authors have previously shown that endogenous serum granulocytecolony stimulating factor (G-CSF) and granulocyte-macrophage-colo

Phase II randomized study of daily gefit

Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy

✍ Yuh-Min Chen; Jacqueline Ming Liu; Teh-Ying Chou; Reury-Perng Perng; Chun-Ming T 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB

## Abstract ## BACKGROUND. The objective of this study was to assess the efficacy of adding chronic, intermittent, low‐dose vinorelbine to gefitinib treatment for patients who had adenocarcinoma of the lung who failed ≥2 regimens of chemotherapy. ## METHODS. Patients were randomized into 2 arms: